Segment Information - Schedule of Business Segments (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Segment Reporting Information [Line Items]
Net sales		$ 2,389	$ 2,611
Cost of sales		(1,913)	(2,057)
Gross Profit		476	554
Selling, General and Administrative Expense		(230)	(265)
Amortization of Intangible Assets		(40)	(41)
Research and Development Expense		(31)	(34)
Other (charges) gains, net (Note 17)		(31)	(14)
Gain (loss) on disposition of businesses and assets, net		3	(1)
Other segment items(2)	[1]	21	11
Operating Income (Loss)		168	210
Depreciation and amortization		180	221
Equity in net earnings (loss) of affiliates		22	55
Capital expenditures	[2]	78	105
Goodwill and intangible assets, net		9,083		$ 9,028
Total assets		23,197		22,857
Increase (decrease) in accrued capital expenditures		(24)	(32)
Engineered Materials [Member]
Segment Reporting Information [Line Items]
Net sales		1,287	1,378
Acetyl Chain [Member]
Segment Reporting Information [Line Items]
Net sales	[3]	1,102	1,233
Operating Segments | Engineered Materials [Member]
Segment Reporting Information [Line Items]
Net sales		1,287	1,378
Cost of sales		(1,012)	(1,109)
Gross Profit		275	269
Selling, General and Administrative Expense		(107)	(103)
Amortization of Intangible Assets		(40)	(40)
Research and Development Expense		(21)	(25)
Other (charges) gains, net (Note 17)		(15)	(11)
Gain (loss) on disposition of businesses and assets, net		4	(1)
Other segment items(2)	[1]	0	0
Operating Income (Loss)		96	89
Depreciation and amortization		109	147
Equity in net earnings (loss) of affiliates		16	49
Capital expenditures		39	37
Goodwill and intangible assets, net		8,663		8,617
Total assets		15,567		15,496
Operating Segments | Acetyl Chain [Member]
Segment Reporting Information [Line Items]
Net sales		1,116	1,261
Cost of sales		(914)	(966)
Gross Profit		202	295
Selling, General and Administrative Expense		(27)	(30)
Amortization of Intangible Assets		0	(1)
Research and Development Expense		(10)	(10)
Other (charges) gains, net (Note 17)		(3)	0
Gain (loss) on disposition of businesses and assets, net		0	0
Other segment items(2)	[1]	0	0
Operating Income (Loss)		162	254
Depreciation and amortization		61	57
Equity in net earnings (loss) of affiliates		3	2
Capital expenditures		30	40
Goodwill and intangible assets, net		420		411
Total assets		5,324		5,265
Segment Reporting, Reconciling Item, Corporate Nonsegment | Corporate Segment and Other Operating Segment [Member]
Segment Reporting Information [Line Items]
Net sales		0	0
Cost of sales		(1)	(10)
Gross Profit		(1)	(10)
Selling, General and Administrative Expense		(96)	(132)
Amortization of Intangible Assets		0	0
Research and Development Expense		0	1
Other (charges) gains, net (Note 17)		(13)	(3)
Gain (loss) on disposition of businesses and assets, net		(1)	0
Other segment items(2)	[1]	21	11
Operating Income (Loss)		(90)	(133)
Depreciation and amortization		10	17
Equity in net earnings (loss) of affiliates		3	4
Capital expenditures		9	28
Goodwill and intangible assets, net		0		0
Total assets		2,306		2,096
Eliminations
Segment Reporting Information [Line Items]
Net sales	[4]	(14)	(28)
Cost of sales		14	28
Gross Profit		0	0
Selling, General and Administrative Expense		0	0
Amortization of Intangible Assets		0	0
Research and Development Expense		0	0
Other (charges) gains, net (Note 17)		0	0
Gain (loss) on disposition of businesses and assets, net		0	0
Other segment items(2)	[1]	0	0
Operating Income (Loss)		0	0
Depreciation and amortization		0	0
Equity in net earnings (loss) of affiliates		0	0
Capital expenditures		0	0
Goodwill and intangible assets, net		0		0
Total assets		0		$ 0
Eliminations | Acetyl Chain [Member]
Segment Reporting Information [Line Items]
Net sales		$ 14	$ 28

[1] Includes Foreign exchange gain (loss), net.

[2] Includes a decrease in accrued capital expenditures of $24 million and $32 million for the three months ended March 31, 2025 and 2024, respectively.

[3] Excludes intersegment sales of $14 million and $28 million for the three months ended March 31, 2025 and 2024, respectively.

[4] Includes intersegment sales primarily related to the Acetyl Chain.